Popular filter options for ipf trials
IPF Clinical Trials
View 41 IPF medical studies.
Oral ORIN1001 for Idiopathic Pulmonary Fibrosis
This trial is testing a new drug, ORIN1001, to see if it is safe and effective in treating adults with idiopathic pulmonary fibrosis (IPF). The trial will have 3 groups of 8 people, who will either receive the new drug or a placebo. The trial will last 28 days.
PET/CT Imaging for Idiopathic Pulmonary Fibrosis
This trial is testing if two different imaging techniques can show evidence of lung inflammation and fibrosis in patients with idiopathic pulmonary fibrosis. The results may help guide future treatment decisions for patients with this condition.
Mucolytic Agent
N-acetyl Cysteine for Idiopathic Pulmonary Fibrosis
This trial will compare the effect of NAC plus standard care with placebo plus standard of care in patients with idiopathic pulmonary fibrosis who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function, first respiratory hospitalization, lung transplantation, or all-cause mortality.
Xenon MRI for Idiopathic Pulmonary Fibrosis
This trial is being done to see if MRI using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments.
NADPH Oxidase Inhibitor
GKT137831 for Idiopathic Pulmonary Fibrosis
This trial is testing a new drug, GKT137831, to see if it can help treat idiopathic pulmonary fibrosis (IPF), a lung disease that until now has had no good treatment options. The drug works by inhibiting an enzyme that produces reactive oxygen species (ROS), which are thought to play a role in the development of IPF. If the drug is effective, it could represent a major breakthrough for IPF patients.
Phase 3 Idiopathic Pulmonary Fibrosis Clinical Trials
View 43 phase 3 idiopathic pulmonary fibrosis medical studies.
Mucolytic Agent
N-acetyl Cysteine for Idiopathic Pulmonary Fibrosis
This trial will compare the effect of NAC plus standard care with placebo plus standard of care in patients with idiopathic pulmonary fibrosis who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function, first respiratory hospitalization, lung transplantation, or all-cause mortality.
Procedure
Sodium Pyruvate Nasal Spray for Idiopathic Pulmonary Fibrosis
This trial will test a nasal spray to reduce coughing and improve lung function in patients with idiopathic pulmonary fibrosis. Results will be measured over 21 days in a double-blind, placebo-controlled trial.
Idiopathic Pulmonary Fibrosis Clinical Trials With No Placebo
View 43 idiopathic pulmonary fibrosis medical studies that do not have a placebo group.
PET/CT Imaging for Idiopathic Pulmonary Fibrosis
This trial is testing if two different imaging techniques can show evidence of lung inflammation and fibrosis in patients with idiopathic pulmonary fibrosis. The results may help guide future treatment decisions for patients with this condition.
Xenon MRI for Idiopathic Pulmonary Fibrosis
This trial is being done to see if MRI using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments.
View More Ipf Trials
See another 20 medical studies focused on ipf.
Frequently Asked Questions
Introduction to ipf
What are the top hospitals conducting ipf research?
When it comes to cutting-edge clinical trials for idiopathic pulmonary fibrosis (IPF), several top hospitals across the United States are leading the charge. In Winston-Salem, North carolina, the Southeastern Research Center is making significant strides with ten active IPF trials and a total of eleven completed trials since their first recorded investigation in 2020. Meanwhile, in Kansas City at the University of Kansas Medical Center, researchers are actively conducting six IPF trials while having completed fourteen studies overall since their initial trial in 2013.
Over in Boston, Massachusetts General Hospital is also playing a crucial role in advancing our understanding and treatment options for IPF. With five ongoing clinical trials focused on this condition and a history of sixteen previous investigations dating back to 2011 when they conducted their inaugural trial. Vanderbilt University Medical Center located in Nashville has made noteworthy contributions as well by currently undertaking five active IPF trials while boasting an impressive twenty-five past studies initiated from their earliest recorded trial back in 2003.
Additionally joining this esteemed list is the Clinical Trials Center of Middle Tennessee situated in Franklin; although relatively new on the scene with only five ongoing IPF clinical trials to date but nevertheless signifies its commitment towards innovative research by initiating its very first exploration into this area just last year-2021
These dedicated hospitals are at the forefront of fighting against idiopathic pulmonary fibrosis – a progressive lung disease that causes scarring of lung tissue - through rigorous scientific research and patient involvement. The combined efforts within these institutions serve not only as beacons of hope for those affected by IPF but also exemplify how medical communities nationwide are working diligently towards finding effective treatments and ultimately discovering a cure for this debilitating condition
Which are the best cities for ipf clinical trials?
When it comes to IPF clinical trials, several cities have emerged as leading centers of research. Philadelphia, Pennsylvania, Los Angeles, California, Dallas, Texas, Birmingham, Alabama, and Winston-Salem, North carolina are among the top cities hosting multiple active trials. These studies investigate various treatments such as Inhaled Treprostinil and BMS-986278 Dose 1 in Philadelphia; N-acetyl cysteine and LTI-03 BID in Los Angeles; CSL312 and Inhaled Treprostinil in Dallas; Inhaled Treprostinil and GKT137831 in Birmingham; INS018_055 and BI 1015550 low dose in Winston-Salem. By conducting these trials across diverse locations nationwide, researchers can collect valuable data that may lead to improved treatment options for patients with IPF.
Which are the top treatments for ipf being explored in clinical trials?
Clinical trials for idiopathic pulmonary fibrosis (IPF) are exploring several promising treatments. Inhaled treprostinil, a drug introduced in 2021, is currently being tested in two active IPF trials. Another potential candidate, INS018_055, has also caught the attention of researchers and is undergoing evaluation in two ongoing clinical trials since its listing in 2022. Additionally, PLN-74809, which entered the scene back in 2019, shows promise as well and is currently being studied in one active IPF trial among three all-time trials dedicated to this condition. These innovative treatments offer hope for patients with IPF as scientists strive to identify effective therapies to combat this debilitating disease.
What are the most recent clinical trials for ipf?
Exciting developments in the field of idiopathic pulmonary fibrosis (IPF) are taking place through recent clinical trials, offering hope and potential advancements for patients. One noteworthy trial is BMS-986278 Dose 1, a Phase 3 study that became available on September 14th, 2023. Additionally, Leramistat has shown promise in Phase 2 trials for IPF since August 30th, 2023. Another exciting avenue being explored involves combining EGCG at a dose of 600 mg with Pirfenidone as part of a Phase 1 trial since August 24th,2023. Furthermore,sodium pyruvate nasal spray treatment is showing promise during its ongoing Phase III clinical trial which began on August15th ,2023.These studies offer immense potential to improve outcomes and quality of life for individuals living with IPF by expanding our understanding and treatment options for this challenging condition.
What ipf clinical trials were recently completed?
Several notable clinical trials focusing on idiopathic pulmonary fibrosis (IPF) have recently achieved significant milestones, presenting new possibilities for the treatment of this debilitating condition. AstraZeneca's trial investigating AZD5055 was successfully completed in November 2021, while Pliant Therapeutics wrapped up their PLN-74809 study in March 2020. Furthermore, The National Institutes of Pharmaceutical R&D Co. Ltd conducted a trial testing NIP292 tablets, which concluded in November 2019. These recent advancements emphasize the ongoing commitment of researchers and offer hope to individuals affected by IPF as they strive to find effective solutions for this complex disease.